Results 221 to 230 of about 4,108,081 (382)

Twenty-Two Health Promotion Pioneers. [PDF]

, 2015
Anderson, David R, Burton, Wayne N, Eng, Eugenia, Goetzel, Ron Z, Green, Larry, Hunnicutt, David, Israel, Barbara, Katz, David, Linnan, Laura, Loeppke, Ron, Minkler, Meredith, Palma-Davis, LaVaughn, Parker, Edith, Pasick, Rena J, Pronk, Nicolaas P, Resnicow, Ken, Schulz, Amy J, Serxner, Seth, Strecher, Victor J, Terry, Paul E, Wallerstein, Nina, Whitsel, Laurie   +21 more
core  

Quantifying the promotion of Cu catalysts by ZnO for methanol synthesis

Science, 2016
Sebastian Kuld, Max Thorhauge, H. Falsig, C. Elkjær, S. Helveg, I. Chorkendorff, J. Sehested   +6 more
semanticscholar   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

"Impact of health promotion practices on health-related quality of life (HRQoL) among geriatric population in Karachi, Pakistan". [PDF]

BMC Public Health
Merchant A.
europepmc   +1 more source

The Essentials of an Efficient Promotion System [PDF]

, 1929
D. Smyth
openalex   +1 more source

Immune cell promotion of metastasis

Nature reviews. Immunology, 2015
T. Kitamura, Binzhi Qian, J. Pollard
semanticscholar   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Assessing the effects of online educational intervention on pharmaceutical promotions: a pre-post study among medical and pharmacy students in Pakistan. [PDF]

Front Pharmacol
Gillani AH, Arshad H, Yang C, Arshed M, Atif N, Bashir K, Abbas Malik HM, Fang Y.   +7 more
europepmc   +1 more source

Prize awards for safety promotion [PDF]

, 1927

openalex   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source